Education
About Us
Working with TipRanks
Follow Us
Cingulate Inc (CING)
NASDAQ:CING
CING Stock Chart & Stats
$3.73
-$0.31(-6.60%)
At close: 4:00 PM EST
$3.73
-$0.31(-6.60%)
Day’s Range― - ―
52-Week Range$3.20 - $6.01
Previous CloseN/A
Volume136.88K
Average Volume (3M)190.99K
Market Cap
$20.74M
Enterprise Value$15.55M
Total Cash (Recent Filing)$6.12M
Total Debt (Recent Filing)$4.58M
Price to Earnings (P/E)―
Beta5.11
Next Earnings
Mar 06, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding5,606,039
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.01
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-26.83
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$12.00Price Target Upside221.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug Delivery TechnologyCingulate's Precision Timed Release (PTR) drug delivery technology can deliver once-daily oral therapies that provide all day efficacy while eliminating the need for boosters.
FDA ApprovalCingulate announced that the FDA accepted its NDA application for CTx-1301 for treating Attention Deficit/Hyperactivity Disorder (ADHD).
Partnerships And CommercializationCingulate previously entered into a partnership with Indegene to commercialize CTx-1301, leveraging their extensive experience and AI-driven services to support a successful launch.
Bears Say
Cingulate Inc News
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $3.20 and its highest was $6.01 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $20.74M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is Mar 06, 2026 which is in 94 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on Nov 13, 2025. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$0.88 by -$0.47.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -0.62.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 5,606,039 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$1.35 in its last earnings report, missing expectations of -$0.88. Following the earnings report the stock price went down -12.368%.
Which hedge fund is a major shareholder of Cingulate Inc?
Currently, no hedge funds are holding shares in CING
Company Description
Cingulate Inc
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
CING Stock 12 Month Forecast
Average Price Target
$12.00
▲(221.72% Upside)
Technical Analysis
Bio Green Med Solution
―
NanoViricides
―
Enlivex
―
FibroBiologics, Inc.
―
Boundless Bio Inc.
―
Ownership Overview
30.02%
Insiders
1.01% Mutual Funds
0.51% Other Institutional Investors
67.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---